In this multicenter descriptive cohort study, we aim to characterize the clinical and laboratory features of patients with sJIA‐SD who developed MAS while receiving IL‐1 pathway–blocking treatment (either anakinra or canakinumab). Here, IL1B is linked to macrophage activation syndrome.